Incidence of serious adverse events
| Serious adverse event . | Placebo, no. (%) N = 30 . | 6 mg senicapoc, no. (%) N = 29 . | 10 mg senicapoc, no. (%) N = 31 . |
|---|---|---|---|
| Sickle cell crisis | 5 (17) | 5 (17) | 5 (16) |
| Pneumonia | 2 (7) | 1 (3) | 1 (3) |
| Acute chest syndrome | 0 | 1 (3) | 0 |
| Staphylococcal sepsis | 0 | 1 (3) | 0 |
| Urinary tract infection | 0 | 0 | 1 (3) |
| Muscle strain | 0 | 0 | 1 (3) |
| Aseptic necrosis of the bone | 0 | 1 (3) | 0 |
| Bronchitis | 1 (3) | 0 | 0 |
| Deep vein thrombosis | 0 | 0 | 1 (3) |
| Serious adverse event . | Placebo, no. (%) N = 30 . | 6 mg senicapoc, no. (%) N = 29 . | 10 mg senicapoc, no. (%) N = 31 . |
|---|---|---|---|
| Sickle cell crisis | 5 (17) | 5 (17) | 5 (16) |
| Pneumonia | 2 (7) | 1 (3) | 1 (3) |
| Acute chest syndrome | 0 | 1 (3) | 0 |
| Staphylococcal sepsis | 0 | 1 (3) | 0 |
| Urinary tract infection | 0 | 0 | 1 (3) |
| Muscle strain | 0 | 0 | 1 (3) |
| Aseptic necrosis of the bone | 0 | 1 (3) | 0 |
| Bronchitis | 1 (3) | 0 | 0 |
| Deep vein thrombosis | 0 | 0 | 1 (3) |
Table lists incidence of all treatment-emergent serious adverse events.